<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37188961</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Refractory alopecia in lupus treated with tofacitinib - a case-based review.</ArticleTitle><Pagination><StartPage>2237</StartPage><EndPage>2241</EndPage><MedlinePgn>2237-2241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06632-6</ELocationID><Abstract><AbstractText>One of the common cutaneous symptoms of systemic lupus erythematosus (SLE) that may have major psychosocial effects in a female is diffuse alopecia. Although Janus kinase inhibitors have shown encouraging results in the treatment of SLE and of alopecia areata in recent studies, tofacitinib in treating refractory alopecia caused by SLE has been rarely documented. The Janus kinases (JAKs) are intracellular tyrosine kinases that play a significant role in the pathophysiology of SLE by participating in a wide range of inflammatory cascades. Here, we reported a 33-year-old SLE patient with long standing (3&#xa0;years) refractory alopecia who took tofacitinib and observed a substantial increase in hair growth. This was sustained at 2-years follow-up even after tapering off glucocorticoids completely. In addition, we reviewed the literature to look for further evidence to support the use of JAK inhibitors for alopecia in SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Rajdeep</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mv</LastName><ForeName>Prakashini</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinduja</LastName><ForeName>Naga</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sethy</LastName><ForeName>Mitanjali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kar</LastName><ForeName>Hemanta</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Sakir</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4631-311X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India. sakir005@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>87LA6FU830</RegistryNumber><NameOfSubstance UI="C479163">tofacitinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531609">Diffuse alopecia</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000505" MajorTopicYN="N">Alopecia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000506" MajorTopicYN="Y">Alopecia Areata</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075242" MajorTopicYN="Y">Janus Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diffuse non-scarring alopecia</Keyword><Keyword MajorTopicYN="N">Hair regrowth</Keyword><Keyword MajorTopicYN="N">Janus kinase inhibitor</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Tofacitinib</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37188961</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06632-6</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06632-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wysenbeek AJ, Leibovici L, Amit M, Weinberger A (1991) Alopecia in systemic lupus erythematosus. Relation to disease manifestations. J Rheumatol 18:1185&#x2013;1186</Citation><ArticleIdList><ArticleId IdType="pubmed">1941821</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun SJ, Lee J-W, Yoon H-J et al (2007) Cross-sectional study of hair loss patterns in 122 Korean systemic lupus erythematosus patients: a frequent finding of non-scarring patch alopecia. J Dermatol 34:451&#x2013;455. https://doi.org/10.1111/j.1346-8138.2007.00309.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1346-8138.2007.00309.x</ArticleId><ArticleId IdType="pubmed">17584322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraz LB, Almeida FA, Vasconcellos MR et al (2006) The impact of lupus erythematosus cutaneous on the quality of life: the Brazilian-Portuguese version of DLQI. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 15:565&#x2013;570. https://doi.org/10.1007/s11136-005-2638-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-005-2638-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DS, Callender VD (2018) Review of quality of life studies in women with alopecia. Int J Womens Dermatol 4:18&#x2013;22. https://doi.org/10.1016/j.ijwd.2017.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijwd.2017.11.007</ArticleId><ArticleId IdType="pubmed">29872671</ArticleId><ArticleId IdType="pmc">5986111</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Lond Engl 392:222&#x2013;231. https://doi.org/10.1016/S0140-6736(18)31363-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter P, Cardoneanu A, Burlui AM et al (2022) Why do we need JAK inhibitors in systemic lupus erythematosus? Int J Mol Sci 23:11788. https://doi.org/10.3390/ijms231911788</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911788</ArticleId><ArticleId IdType="pubmed">36233087</ArticleId><ArticleId IdType="pmc">9569651</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim TM, Ong SJ, Mak A, Tay SH (2022) Type I interferons in systemic lupus erythematosus: a journey from bench to bedside. Int J Mol Sci 23:2505. https://doi.org/10.3390/ijms23052505</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052505</ArticleId><ArticleId IdType="pubmed">35269647</ArticleId><ArticleId IdType="pmc">8910773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Ye Y, Zhao Y et al (2013) Severe diffuse non-scarring hair loss in systemic lupus erythematosus - clinical and histopathological analysis of four cases. J Eur Acad Dermatol Venereol JEADV 27:651&#x2013;654. https://doi.org/10.1111/j.1468-3083.2011.04388.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-3083.2011.04388.x</ArticleId><ArticleId IdType="pubmed">22176340</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Bruce IN, D&#xf6;rner T et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet Lond Engl 401:1011&#x2013;1019. https://doi.org/10.1016/S0140-6736(22)02546-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02546-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayamada S, Tanaka Y (2022) Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert Rev Clin Immunol 18:245&#x2013;252. https://doi.org/10.1080/1744666X.2022.2040988</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2040988</ArticleId><ArticleId IdType="pubmed">35138987</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76:22&#x2013;28. https://doi.org/10.1016/j.jaad.2016.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2016.09.007</ArticleId><ArticleId IdType="pubmed">27816293</ArticleId></ArticleIdList></Reference><Reference><Citation>Almutairi N, Nour TM, Hussain NH (2019) Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatol Basel Switz 235:130&#x2013;136. https://doi.org/10.1159/000494613</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000494613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy Crispin M, Ko JM, Craiglow BG et al (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 1:e89776. https://doi.org/10.1172/jci.insight.89776</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.89776</ArticleId><ArticleId IdType="pubmed">27699252</ArticleId><ArticleId IdType="pmc">5033755</ArticleId></ArticleIdList></Reference><Reference><Citation>King B, Ohyama M, Kwon O et al (2022) Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 386:1687&#x2013;1699. https://doi.org/10.1056/NEJMoa2110343</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110343</ArticleId><ArticleId IdType="pubmed">35334197</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409&#x2013;1417. https://doi.org/10.1007/s00296-011-1999-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-011-1999-3</ArticleId><ArticleId IdType="pubmed">21800117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasni SA, Gupta S, Davis M et al (2021) Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun 12:3391. https://doi.org/10.1038/s41467-021-23361-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23361-z</ArticleId><ArticleId IdType="pubmed">34099646</ArticleId><ArticleId IdType="pmc">8185103</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnardeaux E, Dutz JP (2021) Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep 20:61&#x2013;64. https://doi.org/10.1016/j.jdcr.2021.09.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.09.030</ArticleId><ArticleId IdType="pubmed">35118185</ArticleId><ArticleId IdType="pmc">8792392</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Li J, Shi L (2022) Successful remission with tofacitinib in a patient with refractory bullous systemic lupus erythematosus. Rheumatology 61:e341&#x2013;e343. https://doi.org/10.1093/rheumatology/keac309</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac309</ArticleId><ArticleId IdType="pubmed">35595246</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaller JA, Jaller JJ, Jaller AM et al (2017) Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. Clin Rheumatol 36:971&#x2013;973. https://doi.org/10.1007/s10067-017-3574-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-017-3574-0</ArticleId><ArticleId IdType="pubmed">28210825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Zhao Y, Gong Y et al (2013) Non-scarring patchy alopecia in patients with systemic lupus erythematosus differs from that of alopecia areata. Lupus 22:1439&#x2013;1445. https://doi.org/10.1177/0961203313508833</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313508833</ArticleId><ArticleId IdType="pubmed">24132518</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeshima K, Shibata H (2020) Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus. Ann Rheum Dis 79:674&#x2013;675. https://doi.org/10.1136/annrheumdis-2019-216571</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216571</ArticleId><ArticleId IdType="pubmed">31900301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-L, Liu L-X, Huang Q et al (2021) Case report: reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib. Front Immunol 12:654376. https://doi.org/10.3389/fimmu.2021.654376</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.654376</ArticleId><ArticleId IdType="pubmed">33936080</ArticleId><ArticleId IdType="pmc">8080875</ArticleId></ArticleIdList></Reference><Reference><Citation>Karalilova RV, Batalov ZA, Sapundzhieva TL et al (2021) Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int 41:1743&#x2013;1753. https://doi.org/10.1007/s00296-021-04956-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04956-7</ArticleId><ArticleId IdType="pubmed">34313812</ArticleId><ArticleId IdType="pmc">8390399</ArticleId></ArticleIdList></Reference><Reference><Citation>You H, Zhang G, Wang Q et al (2019) Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis 78:1441&#x2013;1443. https://doi.org/10.1136/annrheumdis-2019-215455</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215455</ArticleId><ArticleId IdType="pubmed">31005902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gialouri CG, Moustafa S, Thomas K et al (2023) Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int 43:421&#x2013;435. https://doi.org/10.1007/s00296-022-05270-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05270-6</ArticleId><ArticleId IdType="pubmed">36635577</ArticleId><ArticleId IdType="pmc">9968274</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>